Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

about

Identification of Potential Therapeutic Targets in the Liver of Pioglitazone-Treated Type 2 Diabetes Sprague-Dawley Rats via Expression Profile Chip and iTRAQ Assay.

P2860

Q54960262-EFF28199-9EB8-4AA6-B50C-46F81903386E

P2860

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

Item

http://www.wikidata.org/entity/Q41242150

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

@en

type

Item

label

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

@en

prefLabel

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

@en

P1476

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

@en

P2093

Srikanth Yandrapalli

http://www.w3.org/2001/XMLSchema#string

Wilbert S Aronow

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

Cardiovascular safety of anti-diabetic drugs

GLP-1 receptor agonists: a review of head-to-head clinical studies

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Association of Cardiometabolic Multimorbidity With Mortality

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

P304

2124-2134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2017.06.70

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28840014

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5542996

http://www.w3.org/2001/XMLSchema#string

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

about

P2860

P2860

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932